Interestingly, a clinical trial showed that, compared to chemotherapy alone, the addition of a recombinant human adenovirus-p53 (Ad-p53) to standard chemotherapy led to a significant reduction in tumor size in locally advanced cervical cancer [23]. The gene discussed is TP53; the disease is cervical cancer.